AstraZeneca PLC - American Depositary Shares (AZN)

It’s what they call a “low dollar market” in that general conditions aren’t easy and there aren’t many slam dunk no-brainer setups.

A fundamental analysis of (NASDAQAZN): This article explores why quality investors may have a look at ASTRAZENECA PLC-SPONS ADR NASDAQ:AZNNASDAQAZN)

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.

Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS). Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.

Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments.

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, CA.1,2

IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.

Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

The top nine American companies by market cap are all worth more than a trillion dollars.

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQAZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)

Soros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options